Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer

Kim A. Margolin, James H. Doroshow, Paul Frankel, Warren Chow, Lucille A. Leong, Dean Lim, Mark McNamara, Robert J. Morgan, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Yun Yen, Neil Kogut, Jeffrey Schriber, Joseph Alvarnas, Susan Stalter

研究成果: 雜誌貢獻文章同行評審

24 引文 斯高帕斯(Scopus)

摘要

We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin, etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel 350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg (cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2. Each cycle was supported by granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8 progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict outcome, the patient's probability of achieving durable remission was significantly associated with the Beyer prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy. The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.

原文英語
頁(從 - 到)903-911
頁數9
期刊Biology of Blood and Marrow Transplantation
11
發行號11
DOIs
出版狀態已發佈 - 十一月 1 2005
對外發佈

ASJC Scopus subject areas

  • 移植

指紋

深入研究「Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer」主題。共同形成了獨特的指紋。

引用此